conference

Synthetic Biologics, Inc., a biotechnology company developing novel drug candidates targeting specific pathogens that cause serious infections and diseases, announced that its latest data on Trimestaâ„¢, regarding cognitive and disability measures in women suffering from multiple sclerosis (MS), will be presented at the 2014 Joint Americas and European Committees…

Biogen Idec, a U.S. biotechnology company specializing in therapies for neurological disorders, autoimmune disorders and cancer, has announced that more than 60 company-sponsored presentations highlighting key data from its extensive portfolio of marketed and investigational multiple sclerosis (MS) therapies were featured during two 2014 neurology conferences. The company…